R. Brett McQueen, PhD, assistant professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, explains how multiple-criteria decision analysis be used to aid in coverage and reimbursement decisions for high-cost, innovative therapies.

Transcript

How can multiple-criteria decision analysis be used to aid in coverage and reimbursement decisions for high-cost, innovative therapies?

MCDA [multiple-criteria decision analysis] provides a structure to quantify preferences for multiple stakeholders but it can also help incentivize evidence generation in these novel spaces in which with traditional value assessment, we haven’t focused on evidence generation in the nontraditional, so it helps not only bring stakeholders together but also incentivize that evidence generation process, which is very important for coverage and reimbursement decision making.

What are best practices for successfully implementing MCDA and transitioning away from other value assessments?

ISPOR has a best practices guideline and taskforce on MCDA, so we’d urge interested readers to go to the ISPOR website to view that. The idea with pValue is not to transition away from traditional value assessment but rather add to it or complement traditional value assessment.